Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Efficacy of B/F/TAF in Pregnant Women with HIV-1
NCT03960645Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUCtau) of Bictegravir. Started Jun 2019; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03960645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03960645.